Thyroglobulin Point of Care Assay for Rapid Detection of Metastatic Differentiated Thyroid Carcinoma
Launched by SOROKA UNIVERSITY MEDICAL CENTER · Oct 14, 2021
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a new test called the Point of Care Thyroglobulin (POC-Tg) assay, which aims to quickly detect metastatic differentiated thyroid cancer (DTC) in lymph nodes. Currently, when doctors suspect cancer in the lymph nodes based on neck ultrasound results, they perform a biopsy and have to wait several days to weeks for results. This delay can affect how quickly patients receive treatment. The POC-Tg test could provide results in just minutes, helping to make faster and more informed treatment decisions.
To participate in this trial, patients must be at least 18 years old and able to sign a consent form. They can be individuals who are being evaluated for thyroid issues or those undergoing surgery for known thyroid cancer. The trial will involve around 250 patients across different clinics and operating rooms. Participants can expect their lymph nodes to be tested using both the traditional method and the new POC-Tg test, allowing researchers to compare the effectiveness of both approaches. Importantly, pregnant women are not eligible to join this study.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Patients who are able and agree to sign the informed consent document.
- • 2. Aged 18 years or older.
- In the FNA clinic arm:
- • 3. Patients evaluated for thyroid nodule/s suspected or known as DTC, accompanied by cervical LN/s suspected as DTC metastasis.
- • 4. Patients following treatment for DTC (partial or total thyroidectomy, with or without compartmental neck dissection), with cervical LN/s suspected as DTC recurrency.
- In the OR arm:
- • 5. Patients operated for known DTC (partial or total thyroidectomy, with or without compartmental neck dissection).
- • 6. Patients operated for DTC recurrency ('completion' and/or compartmental neck dissection).
- • -
- Exclusion Criteria:
- • Pregnant women
- • -
About Soroka University Medical Center
Soroka University Medical Center is a leading academic medical institution located in Beer Sheva, Israel, renowned for its commitment to advancing healthcare through innovative research and clinical trials. As a key player in the Israeli healthcare system, Soroka integrates cutting-edge medical practice with extensive educational programs, fostering a collaborative environment for researchers, clinicians, and students. The center specializes in a wide range of medical fields, emphasizing patient-centered care and evidence-based practices. With a focus on advancing medical knowledge and improving patient outcomes, Soroka University Medical Center actively sponsors and conducts clinical trials that contribute to significant breakthroughs in various therapeutic areas.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Ashkelon, , Israel
Beer Sheva, , Israel
Ramat Gan, Select A State, Israel
Jerusalem, , Israel
Tel Aviv, , Israel
Patients applied
Trial Officials
Uri Yoel, M.D.
Principal Investigator
Soroka University Medical Center, Beer Sheva, Israel
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials